Dr Luis Tavernelli

  • Research Associate (Parasitology)

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2019
Number of items: 5.

2024

Tavernelli, L. E. et al. (2024) Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 ( Tc BDF2) using a fluorescence polarization-based high-throughput assay. Antimicrobial Agents and Chemotherapy, 68(8), 00243-24. (doi: 10.1128/aac.00243-24) (PMID:39028190) (PMCID:PMC11304739)

2023

Simwela, N. V. et al. (2023) A conserved metabolic signature associated with response to fast-acting anti-malarial agents. Microbiology Spectrum, 11(6), e0397622. (doi: 10.1128/spectrum.03976-22) (PMID:37800971) (PMCID:PMC10714989)

2022

Pezza, A. et al. (2022) Essential bromodomain TcBDF2 as a drug target against Chagas disease. ACS Infectious Diseases, 8(5), pp. 1062-1074. (doi: 10.1021/acsinfecdis.2c00057) (PMID:35482332)

2019

Alonso, V. L., Tavernelli, L. E., Pezza, A., Cribb, P., Ritagliati, C. and Serra, E. (2019) Aim for the readers! Bromodomains as new targets against Chagas’ disease. Current Medicinal Chemistry, 26(36), pp. 6544-6563. (doi: 10.2174/0929867325666181031132007) (PMID:30378479)

Tavernelli, L. E., Motta, M. C. M., Gonçalves, C. S., da Silva, M. S., Elias, M. C., Alonso, V. L., Serra, E. and Cribb, P. (2019) Overexpression of Trypanosoma cruzi High Mobility Group B protein (TcHMGB) alters the nuclear structure, impairs cytokinesis and reduces the parasite infectivity. Scientific Reports, 9, 192. (doi: 10.1038/s41598-018-36718-0) (PMID:30655631) (PMCID:PMC6336821)

This list was generated on Wed Nov 13 10:07:32 2024 GMT.
Jump to: Articles
Number of items: 5.

Articles

Tavernelli, L. E. et al. (2024) Identification of novel bromodomain inhibitors of Trypanosoma cruzi bromodomain factor 2 ( Tc BDF2) using a fluorescence polarization-based high-throughput assay. Antimicrobial Agents and Chemotherapy, 68(8), 00243-24. (doi: 10.1128/aac.00243-24) (PMID:39028190) (PMCID:PMC11304739)

Simwela, N. V. et al. (2023) A conserved metabolic signature associated with response to fast-acting anti-malarial agents. Microbiology Spectrum, 11(6), e0397622. (doi: 10.1128/spectrum.03976-22) (PMID:37800971) (PMCID:PMC10714989)

Pezza, A. et al. (2022) Essential bromodomain TcBDF2 as a drug target against Chagas disease. ACS Infectious Diseases, 8(5), pp. 1062-1074. (doi: 10.1021/acsinfecdis.2c00057) (PMID:35482332)

Alonso, V. L., Tavernelli, L. E., Pezza, A., Cribb, P., Ritagliati, C. and Serra, E. (2019) Aim for the readers! Bromodomains as new targets against Chagas’ disease. Current Medicinal Chemistry, 26(36), pp. 6544-6563. (doi: 10.2174/0929867325666181031132007) (PMID:30378479)

Tavernelli, L. E., Motta, M. C. M., Gonçalves, C. S., da Silva, M. S., Elias, M. C., Alonso, V. L., Serra, E. and Cribb, P. (2019) Overexpression of Trypanosoma cruzi High Mobility Group B protein (TcHMGB) alters the nuclear structure, impairs cytokinesis and reduces the parasite infectivity. Scientific Reports, 9, 192. (doi: 10.1038/s41598-018-36718-0) (PMID:30655631) (PMCID:PMC6336821)

This list was generated on Wed Nov 13 10:07:32 2024 GMT.